Merck to Test Promising HIV Vaccines Using NIAID Network
BETHESDA, Maryland-Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.
BETHESDA, MarylandMerck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.
The agreement will enable Merck to evaluate its vaccines in a collaborative effort with the international HIV Vaccine Trials Network (HVTN), which consists of centers at 12 US academic sites and 13 institutions in Africa, Asia, South America, and the Caribbean.
Articles in this issue
Bush to Complete 5-Year Doubling of NIH Budget
CAD Accurate in Digital Images
Campath-1H Safe and Effective in Refractory B-CLL
Involved-Field RT Is Effective in Hodgkin’s Disease
FDA Approves Orfadin for Hereditary Tyrosinemia Type 1
Allovectin-7 Immunotherapy Active in Metastatic Melanoma
HAART Ups Survival in Primary CNS Lymphoma Patients
DX-8951f/Gemcitabine Safe, Active in Advanced Solid Tumors
Pseudomonas aeruginosa Infections After Transplant Rare But Deadly
ODAC Recommends That FDA Approve Zometa for Bone Metastases
CAD Equivalent to Double-Read Mammogram Screening
Language Problems May Contribute to Misconceptions About Trials
Computer-Aided Screening Detects Missed Lung Cancers
High-Dose IMRT Postop Does Not Affect Erectile Function
Topotecan/Doxil Studied as Second-Line Ovarian Cancer Therapy
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
